When: Price reaches $1,061 200 SMA test with bullish reversal confirmation

Then: Deploy 40% of target overweight at $1,061

When: If 5 sessions pass without lower Bollinger hold or MACD contraction trigger AND MACD histogram contracts toward -5.00 with RSI turning above 45 within 5 sessions

Then: Deploy Tranche 1 at current levels regardless to prevent alpha bleed

HOLD; wait for confirmation (daily close above 10 EMA at $1,158 with contracting MACD histogram and RSI above 40, OR test and hold of 200 SMA at $1,061 with bullish reversal candle)

• Actual reward-to-risk is approximately 1-to-1 on stated targets ($1,124 entry, $1,050 stop, $1,200 target), not 2.5-to-1 as claimed
• MACD flipped negative on September 1st with zero bars of contraction on the downside since the flip
• 10 EMA falling for 11 straight sessions from $1,230 to $1,158
• Price pressing into lower Bollinger band at $1,103 which has not yet held
• If lower Bollinger band breaks, next support is 200 SMA at $1,061; below that $950-$1,000 (15%-20% below current levels)
• Aggressive Analyst's debt paydown math (18 months from FCF) is irrelevant to near-term integration and impairment risks
• $8.75 billion acquisition just closed with $3.28 billion in additional intangible purchases and $13.5 billion of new goodwill, none market-tested
• Novo Nordisk pediatric label expansion gives LLY category validation but also a more entrenched competitor with a new indication
• Reddit silence indicates absence of retail floor rather than institutional accumulation
• 40% first tranche size is too large for pre-confirmation entry at a level $20 above support that may break
• Tranche 1 stop placed $54 below the $1,103 support level being tested
• 56% run-up preceding pullback means marginal seller is institutional desk rebalancing, not retail
• Missing first 5% of rebound is frustration, not loss; being wrong on falling knife is open-ended
• Fundamentals and price can disagree violently for extended periods

→ vs aggressive: Reward-to-risk ratio is 1-to-1, not 2.5-to-1; the 2.5-to-1 figure requires reclaiming three resistance levels (10 EMA, 50 SMA, Bollinger middle) with no inclination to do so

→ vs aggressive: MACD has shown zero contraction since September 1st flip; every session the histogram has expanded more negative — this is not 'ugly tape that needs to flush' but active momentum deterioration

→ vs aggressive: Debt paydown in 18 months is irrelevant to integration risk, impairment risk on $13.5B goodwill, and near-term execution uncertainty from unmarket-tested acquisition

→ vs aggressive: Pediatric Wegovy data is a Novo Nordisk readout giving a competitor a label expansion LLY does not have; not an unambiguous tailwind

→ vs aggressive: Reddit silence is absence of potential floor, not proof of institutional accumulation; in a vacuum of retail interest, marginal seller is institutional rebalancing

→ vs aggressive: 'Wait for confirmation' is being mischaracterized as conservative when waiting is the lower-risk approach; the aggressive position is the one with unbounded downside risk on a falling knife

Deploy 20% of target size on confirmed lower Bollinger band hold at $1,103, with 40% staged at 200 SMA ($1,061) and 40% reserved for trend reversal above 10 EMA ($1,158); tighten stop to $1,075 and impose 3-5 session time window for initial entry.

• Aggressive Analyst's reward-to-risk math is ~1:1, not 2.5:1 (entry $1,124, stop $1,050, target $1,200 yields $74 risk vs $76 reward)
• Current technicals show broken 50 SMA, price 5.3% below it, 10 EMA falling 1% per week, and zero MACD histogram contractions on downside for 8 straight sessions
• Conservative overstates downside cost of waiting—missing a Q3 earnings beat and GLP-1 ramp reclaim of $1,280 costs entire forward compounding period, not just 5%
• Bear case target of $950 requires LLY to give back entire post-July run-up plus another $100, inconsistent with 0.50 beta and current fundamental profile
• Wegovy pediatric data expands overall GLP-1 category; LLY's tirzepatide has superior efficacy versus semaglutide in head-to-head data and will file for pediatric label itself
• Recommended tranche architecture: 20% on lower Bollinger hold ($1,103), 40% at 200 SMA test ($1,061), 40% on confirmed trend reversal (daily close above 10 EMA at $1,158 with contracting MACD)
• Tighter stop at $1,075 (below 200 SMA, above spring support) yields ~2.5% risk per tranche vs current $1,050 stop
• 3-5 session time stop: if price chops sideways $1,110-$1,140 without triggering entry, treat as basing pattern and re-evaluate

→ vs aggressive: Reward-to-risk is barely 1:1 at $1,124 entry with $1,050 stop and $1,200 target; 40% deployment into accelerating negative momentum is over-sizing risk

→ vs aggressive: "Dips get shallow because fundamental bid is too strong" framing is ~70% accurate for quality compounders but the other 30% steamrolls positions; current tape shows absent bid for 2 weeks

→ vs conservative: Waiting is not costless—missing a Q3 earnings beat and GLP-1 ramp at overweight sizing costs the entire forward earnings compounding period

→ vs conservative: $950 downside target is a tail scenario requiring either major GLP-1 setback or market-wide deleveraging, not the base case for a 0.50-beta defensive-growth name

→ vs conservative: "Perfect technical confirmation" framing mischaracterizes the middle path; the lower Bollinger hold is a meaningful but not unreasonable hurdle, not perfectionism